Pertuzumab (ZRC-3277) + Pertuzumab (Perjeta®)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Sep 26, 2022 → Sep 6, 2023
NCT ID
NCT05283837About Pertuzumab (ZRC-3277) + Pertuzumab (Perjeta®)
Pertuzumab (ZRC-3277) + Pertuzumab (Perjeta®) is a phase 3 stage product being developed by Zydus Lifesciences for Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05283837. Target conditions include Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05283837 | Phase 3 | Completed |
Competing Products
20 competing products in Metastatic Breast Cancer